🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 142 of 151

  1. befotertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC (Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  2. bendamustine

    Teva Pharma GmbH

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  3. bendamustine

    Teva Pharma GmbH

    Hodgkin Lymphoma

    phase 2 small molecule active

    2 trials

  4. bendamustine and rituximab

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  5. benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    SCLC, Extensive Stage

    phase 2 small molecule active

    1 trial

  6. bevacizumab

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 mab terminated

    1 trial

  7. bevacizumab [Avastin]

    Hoffmann-La Roche

    Liver Cancer

    phase 2 small molecule completed

    1 trial

  8. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  9. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  10. bezuclastinib

    Cogent Biosciences

    Advanced Systemic Mastocytosis (AdvSM)

    phase 2 small molecule active

    1 trial

  11. bilateral permanent occlusion of uterine arteries

    Universal Integrated

    Other Abnormal Uterine and Vaginal Bleeding

    phase 2 other completed

    1 trial

  12. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  13. biricodar dicitrate

    Vertex Pharmaceuticals (Australia) Pty.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  14. bleomycin sulfate

    Children's Hospital of Fudan University

    Childhood Germ Cell Tumor

    phase 2 mab completed

    1 trial

  15. bomedemstat

    United Therapeutics Europe Ltd

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  16. bortezomib/dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acquired Pure Red Cell Aplasia

    phase 2 small molecule completed

    1 trial

  17. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Benign Prostatic Hyperplasia

    phase 2 mab completed

    1 trial

  18. botulinum toxin type A

    Allergan Pharmaceuticals International Limited

    Cervical Dystonia

    phase 2 mab completed

    1 trial

  19. bromocriptine

    Ultragenyx UK Limited

    Stereotyped Behavior

    phase 2 small molecule on hold

    1 trial

  20. budesonide

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 2 small molecule completed

    1 trial

  21. buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 2 small molecule active

    1 trial

  22. buprenorphine taper followed by naltrexone maintenance

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Opioid Dependence

    phase 2 small molecule completed

    1 trial

  23. cP12

    United Therapeutics Europe Ltd

    Thermal Burns

    phase 2 small molecule active

    1 trial

  24. cRGD-ZW800-1

    Disc Medicine

    Squamous cell carcinoma of the larynx and hypopharynx

    phase 2 small molecule active

    1 trial

  25. cRGD-ZW800-1

    Disc Medicine

    Oral cancer

    phase 2 small molecule active

    1 trial

  26. cadonilimab combined +paclitaxel (albumin-bound)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  27. cadonilizumab combined with neoadjuvant radiochemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  28. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  29. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    NovoThirteen

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  30. capecitabine

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  31. carbamazepine

    Ultragenyx UK Limited

    Spasms, Infantile

    phase 2 small molecule completed

    1 trial

  32. carboplatin

    Cardiff Oncology

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  33. cardonilizumab combined with renvastinib

    The First People's Hospital of Lianyungang

    Resectable Clear Cell Carcinoma of the Kidney

    phase 2 small molecule active

    1 trial

  34. casirivimab+imdevimab

    Regeneron UK Limited

    Healthy

    phase 2 small molecule completed

    2 trials

  35. casirivimab+imdevimab

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule terminated

    2 trials

  36. cell sheet pellets and cell sheet fragment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Periodontitis

    phase 2 mab active

    1 trial

  37. cemacabtagene ansegedleucel

    Allogene Therapeutics

    Large B-cell Lymphoma

    phase 2 gene therapy active

    1 trial

  38. cemdisiran

    Alnylam Netherlands B.V.

    Atypical Hemolytic Uremic Syndrome

    phase 2 small molecule terminated

    2 trials

  39. cemiplimab

    Regeneron UK Limited

    Advanced Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  40. cemiplimab

    Regeneron UK Limited

    Carcinoma, Basal Cell

    phase 2 small molecule completed

    1 trial

  41. cemiplimab

    Regeneron UK Limited

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  42. cemiplimab

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  43. cemiplimab (monotherapy)

    Regeneron UK Limited

    Relapsed Solid Tumor

    phase 2 small molecule terminated

    1 trial

  44. cemsidomide

    C4 Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    2 trials

  45. certepetide

    LISATA THERAPEUTICS, INC.

    Pancreas Cancer

    phase 2 small molecule terminated

    1 trial

  46. certepetide

    LISATA THERAPEUTICS, INC.

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  47. cetrelimab, JNJ-63723283

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 2 small molecule active

    1 trial

  48. cetuximab (Erbitux)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.